Push stocks higher
- Gilead Remdesivir trial for Covid-19 has met primary endpoint
- Study to provide info on 5-day duration of therapy
- will share added Remdesivir data from phase 3 shortly
- Seees data from 2nd simple study at the end of May
- 5 day and 10 day Remdisivir treatment see similar results
US stocks are higher on the news with the Dow Jones up before hundred and 73 points. The NASDAQ index is up 200 points
